Altogether, the dual PI3K/mTOR inhibitor NVP-BEZ235 is efficacious against thyroid cancer, among which thyroid tumors with mutant p53 are critically dependent on the inhibition of GSK3β/β-catenin signaling, up-regulating p21 and then inhibiting cell growth in human thyroid cancer. This evidence concerns the gene CDKN1A and thyroid gland carcinoma.